Medpace Holdings, Inc. (NASDAQ:MEDP) Short Interest Up 16.8% in February

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,460,000 shares, an increase of 16.8% from the February 13th total of 1,250,000 shares. Approximately 5.8% of the shares of the company are short sold. Based on an average daily volume of 292,800 shares, the days-to-cover ratio is presently 5.0 days.

Medpace Stock Performance

Medpace stock traded up $4.60 during midday trading on Friday, hitting $324.23. 434,202 shares of the company were exchanged, compared to its average volume of 289,354. The firm has a market capitalization of $9.88 billion, a PE ratio of 25.67, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The business has a fifty day simple moving average of $337.72 and a two-hundred day simple moving average of $339.82.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities analysts expect that Medpace will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $381.44.

Remove Ads

Institutional Trading of Medpace

Several institutional investors have recently bought and sold shares of the business. Centaurus Financial Inc. grew its holdings in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock valued at $505,000 after purchasing an additional 29 shares during the period. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC grew its holdings in Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. grew its holdings in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the period. Finally, Proficio Capital Partners LLC grew its holdings in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.